Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

25 Jul 2022

News You Might Have Missed: July 25th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Breaking News, Law & Politics

23 Jul 2022

Breaking News: DEA Reverses Decision to Ban 5 Psychedelics

Breaking news and a win for psychedelic advocates as the DEA has reversed its decision to schedule 5 psychedelic substances....

By Microdose NewsDesk

Law & Politics

21 Jul 2022

Top Senators Introduce Bill Allowing Patients to Use Psychedelics

Top senators Cory Booker and Rand Paul introduced a bipartisan bill that would clarify laws and give seriously ill patients access to Schedule I drugs, including marijuana and psychedelics....

By Microdose NewsDesk

Industry

20 Jul 2022

Awakn’s Phase 3 Trial Approved for Government Funding

The UK’s National Institute for Health and Care Research (NIHR) has approved grant funding for 66% of the costs of Awakn’s Phase III clinical trial exploring the use of ketamine-assisted...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Don’t Miss

18 Jul 2022

News You Might Have Missed: July 18th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Finance, Industry

13 Jul 2022

Updated: Cathie Wood’s ARK Fund Buys More Atai Stock

Yesterday we received news of additional investment into Atai, with a purchase of 103,977 shares by Cathie Wood's ARK fund....

By Microdose NewsDesk

Science

12 Jul 2022

New Study Shows Mushroom Microdoses Improve Mood and Mental Health

New study shows that 30 days of microdosing is related to improvements in mood, mental health, and psychomotor abilities...

By Microdose NewsDesk

Don’t Miss

11 Jul 2022

News You Might Have Missed: July 11th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Don’t Miss

5 Jul 2022

News You Might Have Missed: July 5th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.